Zane was just 15 months old when his parents noticed something wasn’t right. His eyes, legs and belly were very swollen. At first, it seemed like allergies. As soon as the pediatrician saw Zane, he ...
After a biopsy, I was diagnosed with focal segmental glomerulosclerosis(FSGS), a disease that causes scarring in the parts of ...
Pitt Street Research and Euroz Hartleys have released research notes on Dimerix highlighting upside potential as progresses ...
Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five international databases predicts a substantial, previously underdiagnosed adult NPHS2 ...
Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce ...
Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...
By Siddhi Mahatole and Unnamalai L April 13 (Reuters) - The U.S. Food and Drug Administration has approved the expanded use of Travere Therapeutics' drug to treat a rare kidney disorder, the company ...
Stocktwits on MSN
Travere Therapeutics, Ligand in focus as FDA set to rule on Filspari next week – first FSGS drug at stake
The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026. ・Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.
The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity ...
M any cases of kidney disease in the United States are linked to other serious medical conditions like high blood pressure or diabetes. But there are also forms of kidney disease that strike without ...
MedPage Today on MSN
FDA Approves Sparsentan as First FSGS Treatment
Expanded indication supported by mixed bag of trial data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results